BAL1015

BAL1015 (formerly known as BSC4201) is a potent, selective, and orally bioavailable small-molecule pan-FGFR (Fibroblast Growth Factor Receptor) inhibitor developed by Basilea Pharmaceutica. It targets FGFR1, FGFR2, and FGFR3, which are key drivers in various solid tumors through gene fusions, mutations, or amplifications. BAL1015 is designed as a next-generation inhibitor to provide enhanced potency and potentially overcome resistance mechanisms observed with first-generation FGFR inhibitors. Preclinical data presented at major oncology conferences, such as the American Association for Cancer Research (AACR), have demonstrated its significant anti-tumor activity across multiple FGFR-dependent cancer models and a favorable pharmacokinetic profile.